| New Agreements October 1997 - December 1997# | ||||
| Biotech | Pharma | Type/Product Area | Amount | Terms/Details (Month) |
| Company** | Company | |||
| (Country) | (Symbol/Country) | |||
| Abgenix Inc. | Pfizer Inc. | Research collaboration | $30M | Abgenix gets license fee, equity |
| (subsidiary of | (NYSE:PFE) | and license agreement | (equity; | investment, research funds and |
| Cell Genesys Inc.) | on use of Abgenix's | % ND) | milestones totaling $30M; Pfizer | |
| transgenic XenoMouse | responsible for product develop- | |||
| technology to make fully | ment, manufacturing and market- | |||
| human antibodies to 3 | ing worldwide; Abgenix gets | |||
| of Pfizer's antigen targets | royalties (12/97) | |||
| (undisclosed) | ||||
| Affymetrix Inc. | Novartis Pharma | Affymetrix will supply | ND | Affymetrix gets undisclosed pay- |
| AG (Switzerland) | Novartis with its Gene- | ments based on per-data-point | ||
| Chip instrumentation, | pricing model; payments will | |||
| software and DNA probe | reflect number and nature of genes | |||
| arrays (certain human | analyzed; further details ND | |||
| and mouse genes) to | (12/97) | |||
| monitor gene expression | ||||
| ArQule Inc. | Sankyo Co. Ltd. | Broad collaboration to | $35M | Sankyo gets 3-year subscription to |
| (Japan) | discover and optimize | ArQule's programs to discover | ||
| drug candidates for | new lead compounds and then | |||
| various therapeutic areas | optimize them; ArQule gets pay- | |||
| via ArQule's Mapping | ments for delivery of programs, | |||
| Array and Directed Array | milestones and royalties (11/97) | |||
| programs | ||||
| Arris | Bristol-Myers | Agreement to develop | ND | Bristol-Myers gets exclusive rights |
| Pharmaceutical | Squibb Co. | protease inhibitors for | to any HCV protease inhibitors | |
| Corp. (since merged | (NYSE:BMY) | hepatitis C virus (HCV), | produced in collaboration; Arris | |
| with Sequana | via Arris's Delta tech- | gets research funding, up-front and | ||
| Therapeutics Inc. | nology | milestone payments and royalties | ||
| to form Axys | (12/97) | |||
| Pharmaceuticals Inc.) | ||||
| Aurora | Merck & Co. Inc. | Collaborative research | $100M | Merck will share in development |
| Biosciences Corp. | (NYSE:MRK) | and license agreement | cost of UHTSS and gets co-exclu- | |
| on Aurora's fluorescent | sive access; Aurora gets $33M in | |||
| assay technologies and | committed research funding, lic- | |||
| its ultra-high-throughput | ense fees and delivery payments; | |||
| screening system | Aurora could get more than $100M | |||
| (UHTSS) as well as its | if Merck exercises certain options | |||
| screen development and | for additional systems; Aurora | |||
| screening services, which | also gets royalties on eventual | |||
| Merck will use in drug | product sales (12/97) | |||
| discovery | ||||
| Axiom | Zaiya Inc. and | Joint collaboration to | ND | Axiom gets research funding for |
| Biotechnologies | Nippon Kayaku | identify small-molecule | 3 years as well as license fees, | |
| Inc.* | Co. Ltd. (both | anticancer agents; use of | milestones and royalties; Axiom | |
| Japan) | Axiom's drug discovery | will develop cell-based and bio- | ||
| technologies to evaluate | chemical assays coupled to its | |||
| compound libraries for | high-throughput pharmacology | |||
| lead agents that induce | system (HT-PS) to accelerate func- | |||
| apoptosis in certain | tional profiling of hits; Nippon | |||
| cancers (proprietary | gets exclusive license for Asia and | |||
| molecular target licens- | option to territories outside North | |||
| ed by Zaiya) | America; Zaiya retains product | |||
| rights in North America and will | ||||
| join with Axiom to find U.S. develop- | ||||
| ment and marketing partner (11/97) | ||||
| Biogen Inc. | Merck & Co. Inc. | Collaborative research, | $145M | Biogen gets up-front payment of |
| (NYSE:MRK) | development and license | $15M plus $130M in milestones; | ||
| agreement on drugs for | Merck gets worldwide rights for | |||
| treating asthma and other | certain indications, including | |||
| inflammatory diseases; | asthma, and Biogen gets worldwide | |||
| based on inhibiting VLA4 | rights for other indications, includ- | |||
| receptor molecules (found | ing multiple sclerosis and inflam- | |||
| on most types of white | matory bowel disease; Biogen will | |||
| blood cells); in particular, | pay $21M in milestones to Merck | |||
| an aerosolized anti-VLA4 | for any of Biogen's indications; | |||
| small-molecule drug and | Merck's Japanese affiliate, Banyu | |||
| oral VLA4 inhibitors | Pharmaceutical Co. Ltd., will | |||
| manage clinical development and | ||||
| approvals in Japan of a Biogen com- | ||||
| pound (not yet selected) on which | ||||
| Biogen will retain Japanese market- | ||||
| ing rights; final agreement subject | ||||
| to antitrust considerations (12/97) | ||||
| Biorex Research | Abbott Laboratories | Agreement for joint | $28M | Abbott gets license to bimoclomal |
| and Development | (NYSE:ABT) | development of Biorex's | (equity; | and related compounds; Abbott |
| Co. (Hungary; | bimoclomol product | % ND) | also gets option on right of 1st | |
| wholly owned sub- | (synthetic small mole- | refusal on other future Biorex | ||
| sidiary of BRX Ltd.; | cule that activates | compounds; Abbott bought | ||
| U.K.) | expression of heat shock | 26,200 non-voting convertible | ||
| proteins) for treating | shares at $1,068.75 each in BRX | |||
| complications of | Ltd.; Abbott will commercialize | |||
| diabetes (completed | product; Biorex gets 10% royalty | |||
| Phase II trials in U.K. | (letter of intent 10/97; definitive | |||
| and Hungary for treating | agreement 12/97) | |||
| microalbuminuria and | ||||
| diabetic neuropathy) | ||||
| Chiron Corp. | Bristol-Myers | Licenses to Chiron's | ND | Bristol-Myers and Arris entered a |
| Squibb Co. | hepatitis C virus (HCV) | collaboration to develop HCV | ||
| (NYSE:BMY) | patent portfolio for pro- | protease inhibitors (see separate | ||
| and Arris Pharma- | tease inhibitor research | entry above); Chiron granted the | ||
| ceutical Corp. | (especially use of HCV | partners the 1st nonexclusive | ||
| NS3 protease) | licenses to its patents (12/97) | |||
| Cima Labs Inc. | Novartis Consumer | Development and | ND | ND (12/97) |
| Health Inc. | license option agreement | |||
| (division of Novartis | on use of Cima's Ora- | |||
| AG; Switzerland) | Solv drug delivery tech- | |||
| nology (microencapsu- | ||||
| lated drug formulated | ||||
| into fast-dissolving oral | ||||
| tablet) with Novartis | ||||
| consumer products | ||||
| CollaGenex | Heska Corp. | Collaboration to develop | ND | ND (11/97) |
| Pharmaceuticals | (NASDAQ:HSKA) | certain of CollaGenex's | ||
| Inc. | chemically modified | |||
| tetracyclines (inhibit | ||||
| matrix metalloprotein- | ||||
| ases) for use in compan- | ||||
| ion animal health appli- | ||||
| cations (osteoarthritis, | ||||
| cancer) | ||||
| Cubist | Eli Lilly and Co. | Cubist acquired rights | ND | Cubist licensed rights to develop, |
| Pharmaceuticals | (NYSE:LLY) | to Lilly's Daptomycin | manufacture and market product; | |
| Inc. | antibiotic to treat infec- | Cubist will conduct clinical trials; | ||
| tions caused by drug- | terms include up-front license fee, | |||
| resistant strains of | milestones and royalties (11/97) | |||
| Staphylococcus aureus | ||||
| and Enterococci | ||||
| Dyax Corp.* | Merck & Co. Inc. | Collaborative study | ND | Dyax will develop affinity ligands; |
| (NYSE:MRK) | agreement to discover | Merck will fund research and pay | ||
| and evaluate affinity | milestones and royalties to Dyax | |||
| ligands for vaccine | (10/97) | |||
| purification via Dyax's | ||||
| phage display technology | ||||
| Emisphere | Novartis Pharma | Collaboration on oral | $35M | Novartis gets exclusive worldwide |
| Technologies Inc. | AG (Switzerland) | drug delivery of two | (equity; | rights to oral versions of drugs; |
| selected large-molecule | % ND) | Emisphere gets initial fees, equity | ||
| compounds of Novartis | investment (made in 4 tranches, | |||
| (already on market) | with maximum aggregate purchase | |||
| price of $16M), research funding | ||||
| and milestones totaling $35M in | ||||
| all; Emisphere also gets royalties | ||||
| (12/97) | ||||
| FibroGen Inc.* | Zeneca Ltd. | Licensing agreement on | ND | FibroGen gets exclusive license to |
| (NYSE:ZEN; U.K.) | Zeneca compounds (not | develop and market these com- | ||
| identified) as potential | pounds outside of Europe and | |||
| therapeutics for treating | Japan, where Zeneca retains rights; | |||
| fibrotic disorders and | other terms ND (10/97) | |||
| diseases | ||||
| Genetics Institute | Chugai Pharma- | Functional genomics | ND | Chugai gets access to Genetics |
| Inc. (wholly owned | ceutical Co. Ltd. | agreement; subscription | Institute's library of expressed | |
| subsidiary of | (Japan) | to Genetics Institute's | human secreted proteins, their | |
| American Home | DiscoverEase protein | corresponding cDNAs and a com- | ||
| Products Corp.; | development platform | panion database; futher details | ||
| NYSE:AHP) | (library of human | ND, but similar terms to other | ||
| secreted proteins and | subscriptions (Chugai is 6th sub- | |||
| related database) | scriber) (10/97) | |||
| Genzyme Corp. | Bayer AG | Drug discovery agree- | $35M | Bayer will pay undisclosed up-front |
| (Germany) | ment; use of Genzyme's | fee to access Genzyme's library; | ||
| library of more than 1 million | Bayer will analyze small-molecule | |||
| small molecules to iden- | leads with its high-speed robotic | |||
| tify new drug candidates | screens; when it selects develop- | |||
| for undisclosed disease | ment candidates, Genzyme gets | |||
| targets | milestones as compounds proceed | |||
| through clinical trials (12/97) | ||||
| Genzyme | Parke-Davis | Genomics collaboration; | $9M | If Parke-Davis exercises option to |
| Molecular | (division of | service and license | take nonexclusive license on | |
| Oncology | Warner-Lambert | option agreement on use | SAGE technology for use in its | |
| (division of | Co.; NYSE:WLA) | of Genzyme Molecular's | internal genomics research pro- | |
| Genzyme Corp.) | SAGE technology | grams, it will pay Genzyme Mole- | ||
| (serial analysis of gene | cular $9M in service and license | |||
| expression) in pharmaco- | fees (11/97) | |||
| genomic profiling | ||||
| (changes in gene expres- | ||||
| sion in tissues following | ||||
| exposure to drug can- | ||||
| didates) | ||||
| Geron Corp. | Boehringer | Collaboration on in | ND | Geron gets funding and mile- |
| Mannheim GmbH | vitro cancer diagnostics; | stones; Boehringer Mannheim is | ||
| (Germany) | use of Geron's tech- | responsible for all preclinical and | ||
| nologies for detecting | clinical product development; | |||
| and measuring telomer- | Boehringer Mannheim gets exclu- | |||
| ase expression and level | sive worldwide marketing rights; | |||
| of activity (correlates | Geron gets royalties; Geron retains | |||
| with presence and | copromotion rights in U.S. | |||
| severity of many cancers) | (12/97) | |||
| ICAgen Inc.* | Abbott Laboratories | Research collaboration | $12M | 3-year collaboration with |
| (NYSE:ABT) | on small-molecule drugs | options for renewal; ICAgen gets | ||
| for treating selected | $12M up front plus milestones and | |||
| central nervous system | royalties; Abbott will screen com- | |||
| and urological disorders; | pounds, optimize lead candidates | |||
| use of ICAgen's ion | and perform all phases of product | |||
| channel molecular tar- | development (12/97) | |||
| gets and its gene family | ||||
| chemical libraries to | ||||
| generate selected ion | ||||
| channel targets | ||||
| Idec | Kirin Brewery | License on Idec's | $6.3M | Idec gets up-front licensing fee of |
| Pharmaceuticals | Co. Ltd. (Japan) | vector technology for | $6.3M plus royalties; Kirin is 4th | |
| Corp. | high expression of | and final licensee for this particular | ||
| recombinant proteins in | platform technology (12/97) | |||
| mammalian cells | ||||
| ImmuCell Corp. | Murray Goulburn | Licensing agreement on | $0.3M | License excludes rights to produce |
| Co-Operative Co. | ImmuCell's milk puri- | lactoferrin or immunoglobulins; | ||
| Ltd. (Australia) | fication technology for | ImmuCell gets royalties (11/97) | ||
| use in manufacturing of | ||||
| whey protein isolate | ||||
| (food additive) | ||||
| Incyte | NV Organon (unit | Genomic database | ND | Multiyear agreement; Organon |
| Pharmaceuticals | of Akzo Nobel; | agreement for access to | gets nonexclusive access to data- | |
| Inc. | the Netherlands) | Incyte's LifeSeq gene | base in exchange for annual fees; | |
| sequence and expression | Incyte could get royalties on prod- | |||
| database and LifeSeq | ucts that Organon develops | |||
| GeneAlbum reagent set | (10/97) | |||
| Rhone-Poulenc SA | Genomic database | ND | Multiyear agreement; Rhone-Pou- | |
| (NYSE:RP; France) | agreement for access to | lenc gets nonexclusive access to | ||
| Incyte's LifeSeq gene | database; Incyte gets annual fees | |||
| sequence and expression | and could get milestones and | |||
| database and PathoSeq | royalties on products that result | |||
| microbial database | (12/97) | |||
| Innogenetics NV | Solvay SA | Research collaboration | $49.5M | Solvay will buy 8.3% equity stake |
| (EASDAQ:INNX; | (Belgium) | to discover genes for | (8.3% | for $35.5M (2M shares at $17.75 |
| Belgium) | human diseases, espe- | equity) | each); Solvay also will pay $4M | |
| cially heart disease and | up front and pay $1.5M-$2M for | |||
| central nervous system | R&D support annually for 5 | |||
| disorders, and to use them | years; Innogenetics also gets mile- | |||
| as drug development targets | stones and royalties (11/97) | |||
| IntraBiotics | Pharmacia & | Collaboration on topical | $35M | Companies will codevelop and |
| Pharmaceuticals | Upjohn Inc. | antimicrobial com- | (equity; | promote product in U.S.; they will |
| Inc.* | (NYSE:PNU; | pound IB-367 (synthetic | % ND) | also share profits; Pharmacia gets |
| U.K.) | peptide based on natural | exclusive license in all other terri- | ||
| host defense peptide | tories; IntraBiotics gets royalties; | |||
| protegrin); drug is cur- | IntraBiotics gets reimbursed for | |||
| rently in Phase I trials | half of all development expenses | |||
| for oral mucositis | and also gets $35M in license fees, | |||
| (complication of chemo- | milestones and equity; IntraBiotics | |||
| and radiation therapy) | will manufacture product (10/97) | |||
| Karo Bio AB* | Bristol-Myers | Collaboration on drugs | $40M | 3-year collaboration; Karo |
| (Sweden) | Squibb Co. | for treating metabolic | Bio could get $40M if two thera- | |
| (NYSE:BMY) | disorders (i.e., obesity, | pies developed and approved for | ||
| hypercholesterolemia) | marketing; companies will jointly | |||
| based on thyroid hormone | manage research and preclinical | |||
| receptor beta (TR beta) | development; Bristol-Myers gets world- | |||
| agonists (based on Karo | wide rights to products; Karo Bio | |||
| Bio's 3-D structural data) | gets milestones and royalties (10/97) | |||
| Karo Bio AB* | Merck & Co. Inc. | Strategic alliance on | $80M | Agreement valued at US$80M if |
| (Sweden) | (NYSE:MRK) | drugs and diagnostics | Merck develops and gets regula- | |
| for diseases and con- | tory approval for 2 compounds as | |||
| ditions that are affected | distinct therapies; companies will | |||
| by estrogen receptors | jointly manage research and pre- | |||
| (especially via Karo Bio's | clinical development; Merck gets | |||
| structural data on estrogen | exclusive worldwide rights to com- | |||
| receptors alpha and beta) | pounds; Karo Bio gets up-front and | |||
| milestone payments and R&D | ||||
| funding as well as royalties (11/97) | ||||
| Ligand | Eli Lilly and Co. | Strategic alliance on | $194M | Ligand gets $49M in research |
| Pharmaceuticals | (NYSE:LLY) | products for treating | (equity; | funding over 5 years plus possible |
| Inc. | diabetes and additional | % ND) | extra 3 years of research funding, | |
| metabolic diseases; | $37.5M in equity investment (at | |||
| based on Ligand's | premium to market), $12.5M in | |||
| intracellular receptor | up-front milestones, $75M in addi- | |||
| technology, i.e., retinoid | tional milestones over 8 years for | |||
| X receptor (RXR) | successful development of oral | |||
| agonists including oral | Targretin and 5 other compounds, | |||
| Targretin (currently in | and royalties; Ligand gets its | |||
| Phase II European trials | choice of either rights to one of | |||
| for treating Type II | Lilly's niche cancer products or | |||
| diabetes) | an additional $20M equity invest- | |||
| ment; Ligand also gets milestones, | ||||
| royalties and options to certain co- | ||||
| development rights for a Lilly- | ||||
| selected RXR compound in combi- | ||||
| nation with a selective estrogen | ||||
| receptor modulator (SERM); Lilly | ||||
| gets rights to oral Targretin, exclu- | ||||
| sive rights to 2nd-generation oral | ||||
| diabetes compounds and exclusive | ||||
| rights to Ligand's metabolic dis- | ||||
| ease technology; additional rights | ||||
| to use technology to develop a | ||||
| compound in combination with an | ||||
| SERM for treating cancer; closing | ||||
| subject to completion of Ligand's | ||||
| buyback of Allergan Ligand Ret- | ||||
| inoid Therapeutics (ALRT) shares | ||||
| and restructured rights to ALRT | ||||
| compounds as well as antitrust | ||||
| considerations (deal announced | ||||
| 10/97; finalized 11/97) | ||||
| LeukoSite Inc. | Becton Dickinson | License on chemokines | ND | Becton Dickinson and its units get |
| and Co. (and its | and receptors for use as | exclusive worldwide license to | ||
| units Becton Dickin- | research and diagnostic | commercialize antibodies to sever- | ||
| son Immunocyto- | reagents | al chemokines and chemokine | ||
| metry Systems and | receptors (including CCR5, the co- | |||
| PharMingen; | receptor for HIV) for research use; | |||
| NYSE:BDX) | companies have option to develop | |||
| in vitro diagnostics (10/97) | ||||
| MediGene AG* | Hoechst Marion | Collaboration on viral | $5.8M | 3-year collaboration; MediGene |
| (Germany) | Roussel Inc. (sub- | vectors for gene ther- | will conduct Phase I and II | |
| sidiary of Hoechst | apy, especially Medi- | trials in melanoma; companies | ||
| AG; Germany) | Gene's recombinant | have option of extending collabor- | ||
| adeno-associated virus | ation to include other indications; | |||
| (AAV) vector technol- | Hoechst Marion will fund research | |||
| ogy for ex vivo tumor | and make GMP-quality vectors; | |||
| vaccination in melanoma | collaboration is cosponsored by | |||
| the Bavarian Science Foundation; | ||||
| total value $5.8M (DM10M; con- | ||||
| verted at ratio of DM1.73/US$1) | ||||
| (11/97) | ||||
| MedImmune Inc. | SmithKline | Strategic alliance to | $85M | MedImmune gets up-front payment, |
| Beecham plc | develop human | research funding and milestones | ||
| (NYSE:SBH; U.K.) | papillomavirus (HPV) | totaling $85M; SmithKline gets | ||
| vaccines for preventing | exclusive worldwide rights to vac- | |||
| cervical cancer and | cine technology; companies will | |||
| genital warts; vaccines | collaborate on R&D; MedIm- | |||
| based on MedImmune's | mune will conduct Phase I and II | |||
| virus-like particle tech- | trials and manufacture clinical | |||
| nology for making non- | material; SmithKline will then | |||
| infectious form of virus; | take over final product develop- | |||
| 1st candidate MEDI-501 | ment, manufacturing, regulatory | |||
| (HPV-11) currently in | submissions and marketing; Med- | |||
| Phase I trials | Immune gets royalties; agreement | |||
| subject to clearance under anti- | ||||
| trust law (12/97) | ||||
| Millennium | Monsanto Co. | Broad collaboration | $218M | 5-year agreement; Monsanto |
| Pharmaceuticals | (NYSE:MTC) | in genomics; use of | will form wholly owned subsidiary | |
| Inc. | Millennium's technol- | in Cambridge, Mass., as part of | ||
| ogies to discover and | deal; Millennium will nonexclu- | |||
| develop genomics-based | sively license and transfer to Mon- | |||
| plant and agricultural | santo genomics technologies for | |||
| products | use in R&D of life sciences prod- | |||
| ucts (including pharmaceuticals); | ||||
| Millennium gets $118M in up-front | ||||
| licensing and technology transfer | ||||
| fees ($38M in 1997 and $20M | ||||
| annually for 4 more years); Millen- | ||||
| nium also gets $100M over 5 | ||||
| years for milestones; Monsanto | ||||
| will fund R&D at its new subsid- | ||||
| iary; Millennium gets royalties on | ||||
| certain plant and animal products; | ||||
| Millennium has rights to use cer- | ||||
| tain technologies developed by | ||||
| new company for nonexclusive | ||||
| use outside plant and agricultural | ||||
| areas; collaboration subject to | ||||
| antitrust clearance (10/97) | ||||
| Molecular | DuPont Agricul- | Technology access | ND | DuPont will use microarray system |
| Dynamics Inc. | tural Products | agreement; to further | to study gene expression levels in | |
| and Amersham | (division of E.I. | develop high-throughput | agricultural seed and plant species | |
| International plc | DuPont de Ne- | DNA microarray tech- | and to accelerate development of | |
| (U.K.) | mours and Co.; | nologies | products with greater plant health | |
| NYSE:DD) | and disease resistance; DuPont will | |||
| provide funding and collaborative | ||||
| expertise in exchange for early | ||||
| access to latest microarray tech- | ||||
| nologies (10/97) | ||||
| Molecular | Monsanto Co. | Monsanto (including | ND | ND (12/97) |
| Simulations Inc.* | (NYSE:MTC) | its G.D. Searle & Co. | ||
| unit) has become member | ||||
| of Molecular Simulations' | ||||
| Combinatorial Chemistry | ||||
| Consortium | ||||
| Myriad Genetics | Bayer Corp. | Research collaboration | $54M | Bayer is 1st pharmaceutical |
| Inc. | (subsidiary | to discover gene targets | company to license ProNet | |
| of Bayer AG; | and develop drugs for | database; Myriad gets $54M in | ||
| Germany) | treating dementia and | research and milestone payments; | ||
| depression via Myriad's | Myriad will use its database of | |||
| positional cloning and | Utah families to identify genes of | |||
| ProNet technology | interest; 5-year collaboration; | |||
| (protein interaction net- | Bayer gets worldwide therapeutic | |||
| work; database of human | rights for discoveries in dementia | |||
| proteins and their bio- | and depression; Myriad retains | |||
| chemical pathways) | rights to diagnostics in those areas | |||
| and all rights outside those fields | ||||
| (11/97) | ||||
| NanoSystems | Rhone-Poulenc | Feasibility study to | ND | Rhone-Poulenc Rorer has exclu- |
| LLC* | Rorer Inc. | evaluate new formula- | sive option to license technology; | |
| (subsidiary of | tions of RPR's asthma | further details ND (12/97) | ||
| Rhone-Poulenc SA; | drug triamcinolone | |||
| NYSE:RP; France) | acetonide (respiratory | |||
| steroid), made via | ||||
| NanoCrystal technology | ||||
| (for delivery of poorly | ||||
| water-soluble drugs) | ||||
| NaviCyte Inc.* | SmithKline | Collaboration on use | ND | SmithKline will provide data and |
| Beecham plc | of NaviCyte's compu- | make initial and milestone pay- | ||
| (NYSE:SBH; U.K.) | tational biology tools to | ments; SmithKline gets license to | ||
| identify new candidates | software and computational | |||
| for drug development | models for use with its compound | |||
| (IDEA simulation soft- | libraries (11/97) | |||
| ware enables prediction | ||||
| of drug's pharmaco- | ||||
| kinetic outcome in | ||||
| humans) | ||||
| Neose | McNeil Specialty | Joint program to devel- | ND | ND (11/97) |
| Technologies Inc. | Products Co. | op commercially prac- | ||
| (subsidiary of | tical, large-scale enzy- | |||
| Johnson & John- | matic manufacturing | |||
| son; NYSE:JNJ) | process for certain | |||
| naturally occurring | ||||
| oligosaccharides for | ||||
| human health care | ||||
| applications | ||||
| NetGenics Inc.* | Abbott Laboratories | Use of NetGenics' | ND | Renewable 3-year agreement; |
| (NYSE:ABT) | Synergy software and | NetGenics will tailor Synergy for | ||
| services to manage data | use with Abbott's data; financial | |||
| generated by Abbott's | terms ND (12/97) | |||
| genomics research | ||||
| program | ||||
| Nova Molecular | Amersham | Option agreement on | ND | Amersham Pharmacia will make |
| Inc.* (Canada) | Pharmacia Biotech | sequencing project to | (includes | undisclosed equity investment in |
| Ltd. (Sweden) | identify unique gene | equity) | Nova Molecular; Amersham | |
| variants in 4 specific | Pharmacia gets right to research | |||
| central nervous system- | market applications of DNA | |||
| related genes (pharma- | analysis-related discoveries from | |||
| cogenomics study to | this project (10/97) | |||
| identify responders and | ||||
| non-responders to | ||||
| certain drugs) | ||||
| Pharmacopeia | Bristol-Myers | Research collaboration | $40M | 3-year agreement; Bristol- |
| Inc. | Squibb Co. | to identify and optimize | Myers gets combinatorial librar- | |
| (NYSE:BMY) | small-molecule drug | ies of chemical structures for | ||
| candidates for two | testing in its own internal research | |||
| chemokine receptors | programs; Pharmacopeia gets up- | |||
| related to inflammatory | front payment, annual research | |||
| and immunological | funding and milestones for total | |||
| diseases; use of Pharma- | of $40M; Pharmacopeia could get | |||
| copeia's ECLiPS and | additional milestones from results | |||
| high-throughput screen- | of Bristol-Myers' screening of its | |||
| ing technologies | libraries; Pharmacopeia gets | |||
| royalties (12/97) | ||||
| Pharmacyclics | Alcon Pharma- | Assignment of rights to | ND | Alcon gets worldwide rights to |
| Inc. | ceuticals Ltd. | Lu-Tex photosensitizer | compound for ophthalmic indica- | |
| (affiliate of Alcon | (lutetium texaphyrin, a | tions; Alcon will conduct and fund | ||
| Laboratories Inc., | synthetic molecule that | all costs for development and | ||
| a subsidiary of | captures and focuses | product registration worldwide; | ||
| Nestle SA; France) | light energy) for oph- | Pharmacyclics gets up-front pay- | ||
| thalmic indications, | ment and milestones as well as | |||
| including age-related | royalties (12/97) | |||
| macular degeneration | ||||
| Pharmacyclics | Nycomed ASA | Licensing agreement on | $28M | Nycomed gets exclusive rights to |
| Inc. | (NYSE:NYD; | Lu-Tex photosensitizer | develop and market product in | |
| Norway; in process | (lutetium texaphyrin, a | Europe, Asia, and Central and | ||
| of merging with | synthetic molecule that | South America; Pharmacyclics | ||
| Amersham Inter- | captures and focuses | gets $14M in license fees, mile- | ||
| national plc to | light energy) for photo- | stones and development costs for | ||
| form Nycomed- | dynamic treatment of | initial indication and $14M for subse- | ||
| Amersham plc) | cancer (currently in | quent cancer indication; Pharmacyclics | ||
| Phase II trials for breast | gets royalties and retains rights in | |||
| cancer) | U.S., Canada and Japan; companies | |||
| will share costs for product develop- | ||||
| ment and approval in U.S., but each | ||||
| will make regulatory submissions in | ||||
| own territories; Pharmacyclics will | ||||
| supply bulk drug substance; Nycomed | ||||
| will make finished product (10/97) | ||||
| Qiagen NV | Organon Teknika | Licensing agreement on | ND | Qiagen gets worldwide nonexclu- |
| (the Netherlands) | BV (unit of Akzo | Organon's "boom" | sive license to develop, manufac- | |
| Nobel NV; the | patents (nucleic acid | ture and market products using | ||
| Netherlands) | purification technology) | technology in all markets and for | ||
| all applications, with no field-of- | ||||
| use limitations (11/97) | ||||
| Ribozyme | Parke-Davis | Letter of intent on | ND | Ribozyme Pharmaceuticals will |
| Pharmaceuticals | (division of | collaboration to evaluate | design and synthesize ribozymes | |
| Inc. | Warner-Lambert | specific disease-related | against target genes designated by | |
| Co.; NYSE:WLA) | genes for drug inter- | Parke-Davis; collaboration subject | ||
| vention using Ribo- | to negotiation of definitive agree- | |||
| zyme's target validation | ment; financial terms ND (12/97) | |||
| technology (involves | ||||
| use of ribozymes to dis- | ||||
| cover gene function and | ||||
| validate gene targets) | ||||
| Scios Inc. | The DuPont Merck | Research collaboration | $3M | DuPont Merck will fund research |
| Pharmaceutical Co. | on drugs that prevent | (equity; | and be responsible for developing | |
| or retard disease pro- | % ND) | and commercializing products; | ||
| gression in Alzheimer's; | DuPont Merck will make $3M | |||
| initial focus on use of | equity investment in Scios and pay | |||
| Scios' high-throughput | milestones and royalties on sales | |||
| screens on DuPont Merck | (11/97) | |||
| compounds to identify leads | ||||
| Scriptgen | Hoechst Marion | Collaboration to iden- | $9M | Scriptgen gets $6M in technology |
| Pharmaceuticals | Roussel Inc. (sub- | tify fungal targets and | (equity; | access fees (through 1/98) plus |
| Inc. (IPO pending) | sidiary of Hoechst | develop antifungal drugs | % ND) | $3M equity investment concurrent |
| AG; Germany) | via Scriptgen's high- | with Scriptgen's IPO; Scriptgen | ||
| throughput target | also gets R&D funding, mile- | |||
| identification and | stones and royalties; Hoechst | |||
| validation systems as | Marion will actively participate in | |||
| well as affinity screens | research; Hoechst Marion will be | |||
| responsible for global product | ||||
| development and marketing (10/97) | ||||
| Sepracor Inc. | Schering-Plough | License agreement on | $5M | Schering-Plough gets exclusive |
| Corp. (NYSE:SGP) | Sepracor's patent on | worldwide rights to DCL; Sepra- | ||
| DCL (descarboethocy- | cor gets up-front license fee of $5M | |||
| loratadine, a metabolite | and royalties that escalate over | |||
| of the active agent in | time (12/97) | |||
| Claritin nonsedating | ||||
| antihistamine) | ||||
| Sequana | Parke-Davis | Broad-based genomics | $103M | Sequana gets $103M in combina- |
| Therapeutics Inc. | (division of | alliance to develop | tion of up-front licensing fees, | |
| (since merged | Warner-Lambert | therapeutics for treat- | research funding and milestones; | |
| with Arris Pharma- | Co.; NYSE:WLA) | ing schizophrenia and | Sequana also gets royalties on | |
| ceutical Corp. to | bipolar disorder via | sales of any small-molecule thera- | ||
| form Axys Pharma- | Sequana's capabilities in | peutics; 5-year alliance is extend- | ||
| ceuticals Inc.) | gene discovery, function- | able in 1-year increments to 8 | ||
| al genomics, bioinformatics | years, with concomitant increases | |||
| and high-throughput | in research funding; Parke-Davis | |||
| screening | gets exclusive worldwide rights to | |||
| any small-molecule therapeutics; | ||||
| Sequana retains worldwide rights | ||||
| to recombinant protein, antisense, | ||||
| gene therapy, vaccine, diagnostic, | ||||
| prognostic and pharmacogenetic | ||||
| products and services; Parke- | ||||
| Davis gets nonexclusive license | ||||
| to use certain of Sequana's bio- | ||||
| informatics software tools (11/97) | ||||
| Signal | Ares-Serono | Collaboration to identify | $59M | Signal gets $8M equity investment |
| Pharmaceuticals | Group | small-molecule modu- | (equity; | and $9M over 3 years to fund |
| Inc.* | (Switzerland) | lators in the NF-kB gene | % ND) | research plus about $42M in mile- |
| regulation pathway | stones (at least $10M for each | |||
| (includes broad set of | product resulting from research); | |||
| genes for inflammatory | Signal also gets royalties; Ares- | |||
| molecules); key targets | Serono gets worldwide rights to all | |||
| are proteins IKK-1, IKK-2 | products; Signal retains option to | |||
| and a 3rd regulatory | copromote in U.S.; Signal respon- | |||
| protein as well as NF-kB | sible for target identification and | |||
| inducing kinase | validation, high-throughput screen- | |||
| ing and lead optimization; Ares- | ||||
| Serono will conduct all further | ||||
| product development, approvals | ||||
| and marketing for all indications | ||||
| except in Asia (12/97) | ||||
| T Cell Sciences | Novartis Pharma | Option agreement on | $25M | T Cell gets $5M in annual option |
| Inc. | AG (Switzerland) | TP10 (soluble comple- | (equity; | fees and cost of clinical supplies |
| ment receptor 1; inhibits | % ND) | of TP10 in return for granting | ||
| complement activation) | Novartis a 2-year option to license | |||
| for use in xeno- and allo- | worldwide exclusive rights (except | |||
| transplantation | Japan) to TP10 in fields of xeno- | |||
| and allotransplantation; if Novar- | ||||
| tis exercises option, T Cell gets | ||||
| $20M in equity investment, licens- | ||||
| ing fees and milestones; T Cell | ||||
| could also get additional research | ||||
| funding and royalties; T Cell | ||||
| retains rights to all other indica- | ||||
| tions except those already assign- | ||||
| ed to other partners in Japan | ||||
| (10/97) | ||||
| TheraTech Inc. | The Procter and | Agreement to develop | $35M | Companies will work together on |
| Gamble Co. | transdermal testosterone | clinical development of products; | ||
| (NYSE:PG) | and combination estra- | Procter and Gamble will fund all | ||
| diol/testosterone hormone | development; TheraTech gets R&D | |||
| replacement patches for | payments and milestones of | |||
| women (testosterone | $35M as well as royalties; Thera- | |||
| patch currently in Phase | Tech will manufacture products | |||
| II trials for treating | and retains certain copromotion | |||
| diminished libido in | rights; Procter and Gamble gets | |||
| surgically menopausal | worldwide rights (except Asia) | |||
| women) | (12/97) | |||
| Titan | Novartis Pharma | Agreement on Titan's | $38M | Titan gets up-front payment of |
| Pharmaceuticals | AG (Switzerland) | antipsychotic small- | (equity; | $18M in license fees and reimburse- |
| Inc. | molecule drug Iloper- | % ND) | ment of R&D costs plus a $5M | |
| idone (blocks serotonin | equity investment; Titan will get | |||
| and dopamine); in clin- | $5M milestone when it submits an | |||
| ical development for | NDA in U.S. or Europe and $10M | |||
| treating schizophrenia | on product approval; Novartis will | |||
| and related disorders | fund Phase III trials and product | |||
| registration costs worldwide | ||||
| (except Japan); Titan gets royalties | ||||
| on sales (11/97) | ||||
| Vanguard Medica | Abbott Laboratories | Licensing agreement on | $3M | Abbott has option to develop and |
| Group plc (U.K.) | (NYSE:ABT) | VML 530 (oral dose, | (equity; | commercialize product after Van- |
| inhibitor of 5-lipoxygen- | % ND) | guard completes Phase II trials | ||
| ase activating protein) | (now in preclinical stage); if it | |||
| for treating asthma | exercises option, Abbott will buy | |||
| US$3M in new common stock of | ||||
| Vanguard (at market price) and | ||||
| Vanguard gets royalties on sales | ||||
| (10/97) | ||||
| Vanguard Medica | Sankyo Co. Ltd. | Licensing agreement on | ND | Sankyo gets exclusive rights to |
| Group plc (U.K.) | (Japan) | VML 252 (oral dose, | develop and market product in | |
| calcium-free phosphate | Japan and Far East; Sankyo will | |||
| binding agent) for treat- | make series of payments for rights | |||
| ing hyperphosphatemia | and will cover part of development | |||
| (elevated blood phosphate) | costs; Vanguard will continue clin- | |||
| (currently in U.S. Phase | ical development in U.S. and | |||
| II trial in patients with | Europe; Vanguard will provide | |||
| chronic kidney failure) | bulk compound to Sankyo for its | |||
| own trials; Vanguard gets royalties | ||||
| on Sankyo's sales (10/97) | ||||
| Verigen Inc.* | Italchimici SpA | Licensing agreement | ND | Italchimici will develop and mar- |
| (Italy) | on Verigen's PASSTNF- | ket product in Italy; Verigen gets | ||
| alpha product (porcine- | up-front license fee and royalties; | |||
| derived polyclonal anti- | Verigen retains manufacturing | |||
| body to tumor necrosis | rights (10/97) | |||
| factor-alpha) for use in | ||||
| treating rheumatoid | ||||
| arthritis and Crohn's | ||||
| disease | ||||
| Vical Inc. | Rhone-Poulenc | License on use of | $1M | Rhone-Poulenc Rorer gets exclu- |
| Rorer Inc. | Vical's "naked" DNA | sive worldwide license to technol- | ||
| (subsidiary of | gene delivery technol- | ogy (which will be used by its | ||
| Rhone-Poulenc SA; | ogy to develop certain | RPR Gencell division); Vical gets | ||
| NYSE:RP; France) | gene therapy products | initial fee of $1M plus milestones | ||
| for treating neuro- | and royalties (10/97) | |||
| degenerative diseases | ||||
| Vion | Boehringer | Licensing agreement | $50M | Boehringer Ingelheim gets exclu- |
| Pharmaceuticals | Ingelheim GmbH | on Vion's Promycin | (equity; | sive rights to product outside |
| Inc. | (Germany) | anticancer agent (a | % ND) | North America; Vion gets exclu- |
| bioreductive alkylating | sive copromotion rights in North | |||
| agent; currently in | America; Vion gets up-front | |||
| Phase III trials as adjunct | license fee, milestones and royal- | |||
| to radiation therapy for | ties; companies will share develop- | |||
| treating head and neck | ment costs worldwide; Boehringer | |||
| cancer) | Ingelheim will buy $3M equity in | |||
| Vion (at premium to market); Vion | ||||
| will manufacture and supply prod- | ||||
| uct for all territories (11/97) | ||||
| Virus Research | SmithKline | Collaboration on Virus | ND | Virus Research gets license fees, |
| Institute Inc. | Beecham plc | Research's live oral | milestones and royalties; Smith- | |
| (NYSE:SBH; U.K.) | rotavirus vaccine (virus | Kline gets exclusive worldwide | ||
| causes acute diarrhea | rights; Virus Research will contin- | |||
| and dehydration in | ue to conduct U.S. Phase II clinical | |||
| infants) | trials, after which SmithKline has | |||
| right to assume responsibility for | ||||
| all subsequent development; | ||||
| SmithKline Biologicals will manu- | ||||
| facture product (12/97) | ||||
| Xenova Discovery | EG&G Wallac | Formation of joint | ND | Partners will each license certain |
| Ltd. (subsidiary of | (Finland) | venture, to be called | proprietary technologies to the | |
| Xenova Group plc; | Advant; to provide | joint venture; partners will share | ||
| U.K.) | customized products | profits (12/97) | ||
| and services (e.g., high- | ||||
| throughput screens) for | ||||
| identification of new | ||||
| drug leads | ||||
| NOTES: | ||||
| # This chart contains information on new agreements only, covering the time between 10/1/97 and 12/31/97. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements will appear in the 1/26/98 issue of BioWorld Financial Watch. | ||||
| A chart covering modified agreements and terminated agreements between big pharma and biotech companies for the same time period (10/1/97 - 12/31/97) will also appear in the 1/26/98 issue of BioWorld Financial Watch. | ||||
| ND = Not disclosed, reported and/or available | ||||
| * Private companies are indicated with an asterisk. | ||||
| ** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 17-18. | ||||
